Sana Biotechnology (SANA) Projected to Post Quarterly Earnings on Thursday

Sana Biotechnology (NASDAQ:SANA - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Sana Biotechnology to post earnings of ($0.22) per share for the quarter.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.02. On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Stock Performance

NASDAQ:SANA traded up $0.33 on Monday, hitting $2.15. The stock had a trading volume of 5,326,833 shares, compared to its average volume of 3,318,147. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $9.49. The firm's fifty day simple moving average is $1.93 and its two-hundred day simple moving average is $2.47. The stock has a market cap of $483.65 million, a P/E ratio of -1.54 and a beta of 1.75.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a research note on Thursday, April 24th. Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price on the stock in a research note on Tuesday, March 18th. Finally, Jefferies Financial Group began coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a "buy" rating and a $7.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.80.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.